Valuation: Lord Global Corporation

Market Cap 5.28M 4.63M 4.3M 3.95M 7.44M 510M 7.56M 51.17M 20.02M 249M 19.82M 19.4M 861M P/E 2018 *
-
P/E 2019 -0.6x
Enterprise Value 5.89M 5.16M 4.8M 4.4M 8.3M 569M 8.43M 57.06M 22.32M 278M 22.1M 21.63M 960M EV / Sales 2018
1,290x
EV / Sales 2019 1,135x
Free-Float
25.63%
Yield 2018 *
-
Yield 2019 -
1 month 0
Extreme 0.0002
0
Current year 0
Extreme 0.0002
0
1 year 0
Extreme 0.0002
0
3 years 0
Extreme 0.0001
0
5 years 0
Extreme 0.0001
1
10 years 0
Extreme 0
200,000
Manager TitleAgeSince
Chief Executive Officer 36 2020-01-23
Director TitleAgeSince
Chairman 36 2020-01-23
Change 5-day change 1-year change 3-year change Capi.($)
+100.00%-.--%-.--%-.--% 372
+2.93%-3.73%-32.62%-43.43% 9.55B
+0.33%+3.39%+94.14%+105.99% 9.53B
-4.15%+0.73%-27.31%+23.25% 7.32B
-4.28%+1.13%-40.28%+42.47% 5.27B
-0.58%+5.83%-30.02%-52.74% 4.29B
+0.93%-1.37%-2.15%-4.84% 4.18B
+2.44%+4.21%+116.41%+117.25% 3.93B
-1.24%-0.83%+1.61%-21.69% 3.35B
-4.31%-2.41%-10.64%+1.77% 1.99B
Average +9.21%-2.70%+6.92%+16.81% 4.94B
Weighted average by Cap. -0.48%-2.28%+9.67%+22.97%

Financials

2018 2019
Net sales 2.83K 2.48K 2.3K 2.11K 3.98K 273K 4.04K 27.39K 10.71K 133K 10.61K 10.38K 461K 888 778.36 723.24 664.16 1.25K 85.74K 1.27K 8.6K 3.37K 41.9K 3.33K 3.26K 145K
Net income -6.43M -5.64M -5.24M -4.81M -9.06M -621M -9.2M -62.33M -24.38M -304M -24.15M -23.63M -1.05B -491K -430K -400K -367K -691K -47.38M -702K -4.75M -1.86M -23.16M -1.84M -1.8M -80.02M
Net Debt 651K 570K 530K 487K 916K 62.81M 931K 6.3M 2.47M 30.7M 2.44M 2.39M 106M 608K 533K 495K 455K 856K 58.68M 869K 5.89M 2.3M 28.68M 2.28M 2.23M 99.09M
Logo Lord Global Corporation
27 Health Holdings Corp., formerly Lord Global Corporation, is focused on the business development of its 27Health Inc. subsidiary. 27Health Inc. is focused on financing and marketing, healthcare-related products. The Company distributes the Virolens product in Asia, Australia, New Zealand and other Oceania countries. The Virolens system is a COVID-19 screening device based on microscopic holographic imaging and artificial intelligence (AI) software technology. It uses a digital camera attached to a microscope to analyze saliva samples, with the data run through a computer that is trained to identify the virus from other cells, delivering a result in just 20 seconds. The Virolens system was trained to recognize the COVID-19 virus particles in saliva using a range of samples of COVID-19 virus provided by virologists working on the virus at the University of Bristol.
Employees
-
  1. Stock Market
  2. Stocks
  3. LRDG Stock